BioXcel Therapeutics (BTAI) Scheduled to Post Earnings on Thursday

BioXcel Therapeutics (NASDAQ:BTAI) is set to post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect BioXcel Therapeutics to post earnings of ($0.68) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Tuesday, March 12th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.22. The business had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.17 million. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. On average, analysts expect BioXcel Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioXcel Therapeutics Price Performance

Shares of NASDAQ:BTAI opened at $2.35 on Wednesday. The business’s 50 day moving average price is $2.78 and its 200-day moving average price is $3.16. The firm has a market capitalization of $87.02 million, a PE ratio of -0.38 and a beta of 0.43. BioXcel Therapeutics has a 1 year low of $1.91 and a 1 year high of $29.56.

Analyst Ratings Changes

A number of equities analysts have weighed in on BTAI shares. Bank of America lowered their price objective on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. UBS Group reissued a “neutral” rating and set a $4.00 price objective (down previously from $9.00) on shares of BioXcel Therapeutics in a research note on Wednesday, February 21st. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of BioXcel Therapeutics in a research note on Tuesday, April 23rd. Finally, Canaccord Genuity Group lowered their price objective on BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, March 14th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, BioXcel Therapeutics currently has a consensus rating of “Hold” and an average price target of $16.71.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.